27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Elderly people taking anticholinergic drugs had significant deficits in cognitive functioning and were highly likely to be classified as mildly cognitively impaired, although not at increased risk for dementia. 4 key findings →
Design: cohort study Participants: 372 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
It has been assumed that each MCI subtype is associated with an increased risk for a particular type of dementia. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Depressive symptoms were associated with increased risk of MCI, and this association was independent of underlying vascular disease. 5 key findings →
Design: longitudinal study Participants: 2,220 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease is a common and devastating disease for which there is no readily available biomarker to aid diagnosis or to monitor disease progression. 1 key finding →
Design: case-control study Participants: 50 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among elderly people hospitalization of a spouse is associated with an increased risk of death, and the effect of the illness of a spouse varies among diagnoses. 4 key findings →
Participants: 518,240 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Aging with and without DAT is associated with weight loss; however, weight loss may accelerate before the diagnosis of DAT. 2 key findings →
Design: longitudinal study Participants: 449 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease is the most common cause of dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Reliability of the ACE-R was very good (alpha coefficient=0.8). 2 key findings →
Participants: 241 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
During follow-up, 57 (42%) patients with MCI developed Alzheimer's disease, 21 (15%) developed other forms of dementia, and 56 (41%) remained cognitively stable for 5.2 years (range 4.0-6.8). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These observations suggest that brain amyloid deposition results in low CSF Abeta(42), and that amyloid imaging and CSF Abeta(42) may potentially serve as antecedent biomarkers of (preclinical) AD. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In a cross-section of older adults, vitamin D deficiency was associated with low mood and with impairment on two of four measures of cognitive performance. 4 key findings →
Design: cross-sectional Participants: 80 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Clinical and neuropsychological features contribute to delineating the spectrum of pathology underlying a patient diagnosed with FTLD, but biomarkers are needed that, together with the clinical phenotype, can predict the underlying neuropathology. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The development of common standards represents a first step in a process of use, validation and refinement. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
20 (45%) patients developed a neurological disorder after a mean of 11.5 years from the reported onset of RBD and a mean follow-up of 5.1 years from the diagnosis of idiopathic RBD at our sleep centre. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These results suggest that the SLUMS and MMSE have comparable sensitivities, specificities, and area under the curve in detecting dementia. 3 key findings →
Participants: 702 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Frontotemporal lobar degeneration, corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP) have overlapping clinical features. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study examined the effect of lifelong bilingualism on maintaining cognitive functioning and delaying the onset of symptoms of dementia in old age. 5 key findings →
Participants: 228 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The neuropathologic outcome of amnestic MCI following progression to dementia is heterogeneous, and it includes AD at a high frequency. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The correct diagnosis of Parkinson's disease is important for prognostic and therapeutic reasons and is essential for clinical research. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Subjective memory complaints (SMCs) are common in older people and are often thought to indicate cognitive impairment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The merit of screening for dementia and cognitive impairment has been the subject of recent debate. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia with Lewy bodies (DLB) was considered to be an uncommon cause of dementia until improved neuropathological staining methods for ubiquitin were developed in the late 1980's. Subsequent recognition that 10-15% of dementia cases in older people were associated with Lewy body pathology led to the publication in 1996 of Consensus clinical and pathological diagnostic criteria for the disorder. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Biomarkers are needed to assist in the diagnosis and medical management of various neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), and dementia with Lewy body (DLB). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →